Pyrantel

As a classic broad-spectrum anthelmintic, pyrantel inhibits the cholinesterase of helminths, causing spastic paralysis of the worm body muscles, which makes them lose the ability to attach to the intestinal wall of the host and are finally excreted from the body with intestinal peristalsis. It does not stimulate the worms to scurry around, and its safety is superior to that of early anthelmintic drugs. It is mainly used clinically to treat single or mixed infections of roundworm, hookworm and pinworm, and can be used by both adults and children. It is a commonly used basic drug for the prevention and treatment of community parasitic diseases, especially suitable for batch application in collective deworming scenarios.

The global market size of anthelmintic active pharmaceutical ingredients (APIs) is approximately USD 1.2 billion, with a compound annual growth rate maintained at around 3.2%. Pyrantel occupies nearly 8% of the market share by virtue of its cost-performance advantage. The current competitive landscape is characterized by the dominance of generic drugs. China and India are the core suppliers of pyrantel APIs in the world. More than 60% of the products of domestic manufacturers have passed WHO prequalification, and a large quantity is supplied to global public health procurement projects. After the implementation of centralized procurement, the annual growth rate of pyrantel preparation procurement volume in domestic public medical institutions has reached 41%, which further drives the market demand for upstream APIs.

The original developer of pyrantel is Pfizer, with the original brand name Antiminth. The core compound patent expired globally in 1989. Commonly used clinical dosage forms include oral suspension and tablets, with main specifications of 250 mg per tablet and 50 mg/ml suspension. The original product has been included in the FDA Reference Listed Drug Catalog. Up to now, 3 domestic enterprises in China have obtained A status for their pyrantel APIs through CDE registration, and another 8 enterprises have obtained marketing approval for their pyrantel oral preparations. Among them, corresponding varieties of both tablets and suspensions have been included in the National Reference Listed Drug Catalog. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of pyrantel impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products comply with the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers in the whole process of quality research, stability study and registration, providing stable material basis support for the compliant production of enterprises.